

Developing the drug candidates for psoriasis treatment using small molecule with IRAK-1/4 inhibition

Donghwa Pharm



DONGWHA PHARM

IMMUNOLOGY	Candidate
Product Type	Small molecules (NCE)
Indication	Psoriasis
Target	Interleukin-1 receptor-associated kinase(IRAK) 1/4
MoA(Mechanism of Action)	<ul style="list-style-type: none"> • Inhibits the downstream signaling of IRAK 1 and 4 through the TLR-IL1R-IRAK pathways • Binds to ATP-binding pocket of IRAK1 and 4, simultaneously
Competitiveness	<ul style="list-style-type: none"> • First-in-class small molecule inhibitor • Improved psoriatic lesions in IMQ(Imiquimod) induced mouse model and decreased inflammatory cytokine in LPS challenge model. • No adverse events found in short-term toxicity test (2-weeks, non-GLP)
Development Stage	Candidate
Route of Administration	Oral Administration